Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients. The data reiterates the role of lumbar total disc replacement in delaying the progression of adjacent segment disease (ASD).
Previously, lumbar fusion had been reported to be responsible for a rate of ASD as high as 28.6% at 5 years.
activ-L received FDA Premarket Approval in 2Q15 for treatment of 1-level lumbar degenerative disc disease.
Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients. The data reiterates the role of lumbar total disc replacement in delaying the progression of adjacent segment disease (ASD).
Previously,...
Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients. The data reiterates the role of lumbar total disc replacement in delaying the progression of adjacent segment disease (ASD).
Previously, lumbar fusion had been reported to be responsible for a rate of ASD as high as 28.6% at 5 years.
activ-L received FDA Premarket Approval in 2Q15 for treatment of 1-level lumbar degenerative disc disease.
Copy to clipboard 
